View Older Stories View More Recent Stories
-
Energy Fuels (UUUU) Provides Corporate Update; Roth Capital Reiterates Buy
-
Roth Capital Says Sequential Brands (SQBG) Recent Sell-Off is 'Overblown'; Reiterates Buy
-
Janney Announces Hiring of Additional New Research Analyst Covering Biotechnology
-
Energous Corporation Announces Closing of Public Offering of Common Stock
-
Roth Capital Downgrades Aptose Biosciences (APTO) to Neutral
-
Roth Trims PT on JinkoSolar (JKS) to $35; Sector Sentiment Pressures Amid Solid Q3 Results, Guidance
-
Galectin Therapeutics (GALT) Prices 4.76M Securities Purchase Agreement
-
Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering
-
Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering
-
High Wafer Shipments Drive Revenue Beat for ReneSola (SOL); Roth Capital Remains Neutral
-
Streetinsider.com's Hot Lunchtime Reads 11/19: (UVE) (CLDN) (BA) (OC)
-
salesforce.com (CRM) Reports Record Revenue; Roth Capital Reiterates Buy
-
MeetMe (MEET) Looks Undervalued as the Match IPO Set to Open - Roth Capital
-
Roth Capital Sees Considerable Headwinds for Keurig Green Mountain (GMCR) in 2016
-
Ligand Pharma (LGND) Provides Updates at Analyst Day; Roth Capital Raises Price Target to $144
-
Roth Affirms Keurig Green Mountain (GMCR) at Neutral; Headwinds Remain into FY16
-
Unique Fabricating (UFAB) Reports Slight EPS Beat; Roth Capital Cuts Price Target to $15
-
Enphase Energy (ENPH) Provides Details on Cost Reduction at Analyst Day; Roth Capital Cuts Price Target to $1.90
-
Energous (WATT) Prices 2.61M Common Stock Offering at $6.90/Share
-
Energous Corporation Prices Public Offering of Common Stock
-
Roth Capital Bullish on Recent BioBlast Pharma (ORPN) Hires; Reaffirms at 'Buy'
-
Energous Corporation Announces Proposed Public Offering of Common Stock
-
Roth Capital Cuts Price Target on Marathon Patent Group (MARA) Following 3Q Beat
-
Roth Lifts PT on Hydrogenics (HYGS) to $13 Following 'Milestone' Order
-
Notable Analyst Rating Changes 11/16: (APH) (CEMP) (LLY) Upgraded; (MNKD) (CWEI) (CDTI) Downgraded
-
Higher Shares Outstanding Offset CorMedix (CRMD) Revenue Miss; Roth Capital Remains Neutral
-
Weak Oil Prices Weigh on Superior Drilling Products (SDPI); Roth Capital Remains Neutral
-
Roth Capital Cuts Price Target on Flamel Technologies (FLML) Following Slight 3Q Miss
-
Juniper Pharma (JNP) Announces Pipeline Candidates at Analyst Day; Roth Capital Reiterates Buy
-
Roth Capital Downgrades Clean Diesel Technologies (CDTI) to Neutral
-
Roth Capital Downgrades Clayton Williams Energy (CWEI) to Sell
-
Roth Reaffirms VBL Therapeutics (VBLT) at 'Buy'; Financing Overhang Removed, Partnership Now Key Focus
-
Notable Analyst Rating Changes 11/13: (BBG) (WMT) (YELP) Upgraded; (FFIV) (FME) (RBY) Downgraded
-
3Q Results Show Disparity in Così's (COSI) Best and Worst Performing Stores; Roth Capital Reiterates Buy
-
Alcobra Ltd. (ADHD) Prices 6.18M Ordinary Stock Offering at $6.50/Share
-
Alcobra Ltd. Prices Public Offering of Ordinary Shares
-
Alcobra Ltd. Prices Public Offering of Ordinary Shares
-
RAVE Restaurant Group (RAVE) Reports Rough Same Store Comps; Roth Capital Cuts Price Target to $14
-
Roth Capital Starts Outerwall Inc. (OUTR) at Buy
-
Roth Capital Starts Glu Mobile (GLUU) at Buy
-
Roth Capital Downgrades Digital Ally (DGLY) to Neutral Following Disappointing Q3
-
Roth Capital Raises Price Target on Future Fuel (FF) Following 3Q Revenue Beat
-
FX Hits Middleby Corp's (MIDD) Net Sales; Roth Capital Cuts Price Target to $130
-
Good Execution by Horizon Global (HZN) Drives Revenue Growth; Roth Capital Raises price Target to $13
-
Telesta Therapeutics Publishes its Q1, 2016 Financial Statements and Provides Corporate Updates
-
APTO-253 Remains in Focus for Aptose Biosciences (APTO); Roth Affirms at 'Buy'
-
Zosano Pharma (ZSAN) Reported 3Q EPS Miss; Roth Capital Reiterates Buy
-
3Q EPS Miss Driven by Decline in Revenue; Roth Capital Reiterates Buy on Iconix Brand Group (ICON)
-
Hydrogenics (HYGS) Reports Mixed 3Q Results; Roth Capital Reiterates Buy
-
Roth Capital Reiterates Buy on Canadian Solar (CSIQ) Following 3Q

